However, ASAP3 expression was significantly lower in bladder urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck cancer (HNSC), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), Kidney renal papillary cell carcinoma (KIRP), lung squamous cell carcinoma (LUSC), Pheochromocytoma and Paraganglioma (PCPG), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC) when compared with adjacent normal tissues (Figure 1b). Here, ASAP3 is linked to bladder transitional cell carcinoma.